A study on the application method for prevention/reduction of the local irritation with the benzoyl peroxide preparations for acne vulgaris patients.

A study on the application method for prevention/reduction of the local irritation with the benzoyl peroxide preparations for acne vulgaris patients. - A study for the prevention of local irritation of the BPO preparation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031922

Enrollment

120

Registered

2018-03-27

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne vulgaris

Interventions

Gradual increase application group (Epiduo Gel) 20 subjects

BPO preparation use experience. Application once a day consecutive for appropriate amount, 12 weeks Non-gradual increase application group (Epiduo Gel) 20 subjects

BPO preparation use experience. Application once a day consecutive for appropriate amount, 12 weeks Gradual increase application group (BPO Gel) 40 subjects

BPO preparation use experience 20 subjects,no BPO preparation use experience 20 subjects. Application once a day consecutive for appropriate amount, 12 weeks Non-gradual increase application group (BP

BPO preparation use experience 20 subjects,no BPO preparation use experience 20 subjects. Application once a day consecutive for appropriate amount, 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Moderate acne vulgaris (6-20 inflammatory rashes on one side of the face) 2) Written consent provided after receiving an explanation of the study content 3) Age >=20 years at the time of obtaining consent.

Exclusion criteria

Exclusion criteria: 1) Treated for acne vulgaris within one month before the study 2) Contraindicated for the investigational drugs 3) Continuous use of nonsteroidal anti-inflammatory drugs (such as ibuprofen) 4) Pregnant or possibly pregnant women, lactating women, and women who wanted to become pregnant during the study period. 5) Judged as ineligible by the physician directing the study 6) Participation in another clinical study or post-marketing surveillance of other drugs for acne vulgaris within six months before the study.

Design outcomes

Primary

Measure	Time frame
A local irritating evaluation (accompanying symptom) during testing period of 12 weeks: Erythema, desquamation, skin drying, itching, irritation / incandescence	—

Countries

Japan

Contacts

Public ContactYoshitaka Ogaki

EBC&M LLC. Clinical Business Department

yoshitaka_ogaki@ebc-m.com03-6435-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026